Top segments and regional performance

Last year, the company generated ‪2.12 T‬ JPY, the most of which — ‪2.03 T‬ JPY — came from its top-performing segment, Medical Drugs, compared to ‪1.80 T‬ JPY the previous year. The greatest contribution came from United States, which accounted for ‪749.40 B‬ JPY last year, with ‪642.22 B‬ JPY the year before.